ATOS Atossa Therapeutics, Inc.

NASDAQ
$2.42

Atossa Therapeutics, Inc. (ATOS) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.92 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +2.1% since its last earnings release on August 7, 2026.

Atossa Therapeutics, Inc. Beat Consensus Estimates
Friday, August 7, 2026 · 8:45 AM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 6
Friday · 8:45 AM ET
Earnings Whisper
-
vs ($0.92)
Rev est $999
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.57

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming breast cancer treatment through innovative science and patient-focused solutions.

Sector

Healthcare

Industry

Biotechnology